Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy
Crossref DOI link: https://doi.org/10.1186/1471-2407-14-813
Published Online: 2014-11-05
Published Print: 2014-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Choy, Edwin
Butrynski, James E
Harmon, David C
Morgan, Jeffrey A
George, Suzanne
Wagner, Andrew J
D’Adamo, David
Cote, Gregory M
Flamand, Yael
Benes, Cyril H
Haber, Daniel A
Baselga, Jose M
Demetri, George D
License valid from 2014-11-05